{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:26:20Z","timestamp":1758054380562,"version":"3.44.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) is an increasing global pandemic, frequently complicated by diabetic kidney disease, that may result in end stage kidney disease and increased cardiovascular morbidity and mortality. The 2020 KDIGO guidelines recommend SGLT2 inhibitors and GLP1RAs for cardio-renal protection in patients with T2DM and kidney disease. This study aimed to evaluate the implementation of the 2020 KDIGO guidelines among adult diabetic patients receiving nephrology care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>This retrospective study included 587 patients with T2DM and chronic kidney disease treated in a single nephrology clinic between 1 May 2021 and 31 May 2022. Demographic, diabetes related, and CKD-related data was assessed. The utilization of the 2020 KDIGO recommended medications was analyzed during the study period, along with factors influencing treatment decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The findings revealed a low initial utilization of recommended medications, with only 12.9% and 10.4% of patients treated with SGLT2i and GLP1RA, respectively. Only a modest, but significant, increase in SGLT2i usage was observed by the end of the study period. Factors associated with underutilization of SGLT2i and GLP1RA included older age and decreased kidney function. The study also highlights a significant gap between the recommendations given by nephrologists during the study period and the actual use of recommended medications in the last clinic visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In conclusion, the study provides insights into the challenges of implementing KDIGO guidelines in real-world nephrology clinical setting. Further research is needed to explore the reasons behind low adherence to guidelines and strategies to improve compliance, ultimately enhancing patient outcomes in the management of kidney disease in T2DM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneph.2025.1664369","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:37Z","timestamp":1757909617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world implementation of the 2020 KDIGO guidelines for diabetes management in chronic kidney disease: a single-center retrospective study"],"prefix":"10.3389","volume":"5","author":[{"given":"Nomy","family":"Levin-Iaina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"El\u2019Nasasra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Reiner-Benaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"510","author":"Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/dme.13324","article-title":"Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies","volume":"34","author":"Koye","year":"2017","journal-title":"Diabetes Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"32","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S010","article-title":"Microvascular complications and foot care: standards of medical care in diabetes","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.11.003","article-title":"Glycemic control as primary prevention for diabetic kidney disease","volume":"25","author":"Mac Isaac","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD010137","DOI":"10.1002\/14651858.CD010137.pub2","article-title":"Glucose targets for preventing diabetic kidney disease and its progression","volume":"6","author":"Ruospo","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.777428","article-title":"Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease","volume":"9","author":"Scheen","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016121372","article-title":"Therapeutic considerations for anti hyperglycemic agents in diabetic kidney disease","volume":"28","author":"Neumiller","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.11.002","article-title":"Treatment of diabetic kidney disease with hypertension control and renin angiotensin system inhibition","volume":"25","author":"Patney","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta analysis of randomized controlled trials","volume":"37","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(17)30069-1","article-title":"The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes","volume":"43","author":"Thomas","year":"2017","journal-title":"Diabetes Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Group KDIGO","year":"2020","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/CPAA.S82008","article-title":"The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies","volume":"8","author":"Davies","year":"2016","journal-title":"Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.06.008","article-title":"Managing the course of diabetic kidney disease: from the old to the new","volume":"42","author":"Goldenberg","year":"2018","journal-title":"Can J Diab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108204","DOI":"10.1016\/j.jdiacomp.2022.108204","article-title":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","volume":"36","author":"Christine","year":"2022","journal-title":"J Diab Comp"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009-2014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B33","first-page":"S449","article-title":"Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes: a secondary analysis of the multinational CAPTURE study (abstract 945)","volume":"63","author":"Vencio","year":"2020","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B35","volume-title":"R: A Language and Environment for Statistical Computing","year":"2023"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e021084","DOI":"10.1161\/JAHA.121.021084","article-title":"Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus","author":"Nargesi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.clinthera.2020.12.015","article-title":"Prescribing in type 2 diabetes patients with and without cardiovascular disease history: A descriptive analysis in the UK CPRD","volume":"43","author":"Farmer","year":"2021","journal-title":"Clin Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-022-01731-w","article-title":"Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study","volume":"23","author":"Hao","year":"2022","journal-title":"BMC Primary Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2192\u2013207","DOI":"10.1007\/s12325-022-02105-5","article-title":"The economic burden of insulin injection-induced lipohypertophy. Role of education: the ISTERP-3 study","volume":"39","author":"Gentile","year":"2022","journal-title":"Adv Ther"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1664369\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:38Z","timestamp":1757909618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1664369\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":39,"alternative-id":["10.3389\/fneph.2025.1664369"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1664369","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1664369"}}